BridgeMD
New treatment option for Mechanomyography
Official title The TOF3D Mechanomyograph. Evaluation of a New Device for Assessment of the Neuromuscular Block.
ClinicalTrials.gov ID: NCT07371377
What this study is testing
- What it's testing
- In clinical anesthesiologic practice, most institutions use acceleromyography in order to assess the degree of a neuromuscular block. The aim of the present study is to assess a new device using mechanomyography.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 65
You may be able to join if
- patients scheduled for surgery requiring general anesthesia with neuromuscular blocking agents
You likely can't join if
- anticipated or known difficult airway
- increased risk for aspiration
- pregnancy
- neuromuscular disorders
The study team makes the final eligibility decision.
Where it's taking place
- Bad Hersfeld, Germany
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 65 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Bad Hersfeld, Germany. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.